K28 B Congenital HSV KBK
K28 B Congenital HSV KBK
K28 B Congenital HSV KBK
Herpes Infections
Herpes from the
Greek to creep,
crawl
Herpetic
eruptions
described as early
as 100 AD
1960s HSV1 and
HSV2 differentiated
HHV1
HHV2
HHV3
HHV4
HHV5
HHV6
HHV7
HHV8
HSV1
HSV2
VZV
EBV
CMV
Causes?
Neonatal HSV
1 in 2,500-5,000 deliveries / 500-1500 per yr.
Birth to 7 weeks of life
HSV2 = 70-75%, HSV1 = 25-30%
3 Main Types
Skin, Eye, Mouth (SEM)
CNS
Disseminated Disease (DISSEM)
Routes of Transmission
85% via infected
maternal genital
tract
Ascending
infection?
En route
10% postpartum
5% (or less)
intrauterine/conge
nital infection
Congenital HSV
Rare, most
devastating
Only 50 cases
described
Skin vesicles
Chorioretinitis
Microcephaly
Micro-ophthalmia
IUGR
Archival Photo:
HSV In Utero
Healed by Time
Of Birth With
Microcephally
Groin Vesicles
16 Days of Life
HSV-1, This Infant
Had a Cardiac Cath
(Groin Line)
At 3 Days of Life
SEM (cont)
Long term
neurologic
sequelae seen in
30% of cases
even if treated
Ophthalmology
involvement
Radiographic Findings
Disseminated Disease
Approximately 20%
of all infections
Hepatitis
Pneumonitis
DIC
Signs
Postnatal acquisition
Most commonly
HSV1
Moms with HSV
Mask
Breastfeeding
O.K. if without
lesions
Contacts
Personnel with
an active herpetic
whitlow should
not have direct
patient care of
neonates.
Family
transmission has
been described
Herpes Simplex
Approximately 5% of the general
population has been diagnosed
with genital herpes but
approximately 20-30% of women
may be infected with HSV-2
Viral shedding occurs without
identifiable lesions on 1-3% of days
OB Management
70s-80s weekly HSV cultures
1988 patient examined at delivery,
Cesarean delivery if: (no data)
Identifiable genital lesions
Patient describes prodromal symptoms
Diagnostics
HSV Cx positive
in 1-2 days
(cytopathic effect)
DFA
sensitivity/specific
ity in the 75%85% range
PCR Testing
Detects minute
amounts of DNA,
RNA
DISSEM 93%
CNS 76%
SEM 24%
Diagnostics (cont)
Surface cultures
Mouth (40-50%)
Eyes (25%)
Rectum
Skin
Cultures
Stool
Urine
CSF >100 WBC/Inc. Pro
Tzanck neither
sensitive nor specific
Treatment - Acyclovir
SEM infections
60mg/kg/day divided q8h for 14 days
May be lengthened to 21 days in the near
future
Oral Acyclovir needed later in life?